Resonance Health Ltd · ASX:RHT
Resonance Health — Shareholder Meeting (November 2010)
12 slides from Resonance Health's shareholder meeting presentation, Nov 17, 2010
Slide 1: Annual General Meeting
For personal use only Resonance Health Ltd ACN 006 762 492 Annual General Meeting 17 November 2010
Slide 2: Resonance Health Ltd (RHT)
Resonance Health Ltd (RHT) For personal use only • Solid growth in FerriScan sales volume • Revenue growth of 18% in the clinical use of FerriScan • Strong growth in the number of centres providing FerriScan world wide • Novartis relationship developed representing significant FerriScan sales potent
Slide 3: FY 2010: FerriScan Growth up 29%
FY 2010: FerriScan Growth up 29% For personal use only
Slide 4: US Expansion: US hospitals provide FerriScan
US Expansion 28 US hospitals provide FerriScan (100% ↑) For personal use only 14 New US FerriScan Centres in FY 2009/2010 14 Pre-existing US FerriScan Centres 5 US centres in set up progress for FerriScan
Slide 5: FerriScan now available in countries
FerriScan now available in 24 countries For personal use only
Slide 6: Beyond FerriScan: Liver Disease Market Opportunity
Beyond FerriScan Liver Disease Market Opportunity For personal use only • Liver disease is one of the top 10 causes of death in the US • Liver disease is the only major cause of death still increasing year-on-year in the UK Leading causes • Viral Hepatitis – 170m world wide are infected with HepC •
Slide 7: Liver Disease Progression
Liver Disease Progression For personal use only
Slide 8: Liver Biopsy
Liver Biopsy Invasive Diagnostic Method for Fatty Liver and For personal use only Liver Fibrosis
Slide 9: New Product in Development: Liver Fat and Liver Fibrosis Measurement
New Product in Development Liver Fat and Liver Fibrosis Measurement For personal use only • Proof of Concept Completed for Fat and Fibrosis • Study of 59 people completed with promising results • USA Regulatory Submission for Liver Fat Measurement • 510k submission Q4 2010, 90 day approval process •
Slide 10: Resonance Health Product Portfolio
Resonance Health Product Portfolio For personal use only Proof of USA On Reimbur Research concept Build Validate -sement 510K Market (Canada/ FerriScan® UK) (EU & Cardiac T2* (USA) Australia) Liver Fat test Fibrosis Test
Slide 11: FY 2010: Financial Results
FY 2010: Financial Results • Revenue associated with the routine clinical use of FerriScan grew For personal use only 18% and continues to grow • Revenue associated with the use of FerriScan in clinical trials declined, as some clinical trials using FerriScan were completed • Research and developmen
Slide 12: Summary
Summary For personal use only • Strong future for Resonance Health • Solid growth in the commercial use of FerriScan • Novartis relationship developed in global iron overload market • Continued focus on gaining reimbursement for FerriScan • Distributors engaged for entry into target regions • Engage
Resonance Health — Shareholder Meeting (November 2010) on 6ix